Transcriptional activities of estrogen receptor alpha and beta in yeast properties of raloxifene.

Raloxifene represents a potent compound for the prevention and treatment of osteoporosis and cardiovascular disease in postmenopausal women. Raloxifene exhibits targeted antiestrogenicity in breast and uterus, but acts as an agonist in bone and liver. This synthetic selective estrogen receptor modulator binds both estrogen receptors alpha and beta. The molecular mechanisms by which raloxifene exerts agonistic or antagonistic activity are still not resolved. Therefore, the binding behavior of raloxifene to estrogen receptors and its effects on DNA binding and transactivation were studied. The equilibrium binding affinity of raloxifene by displacing radiolabeled 17beta-estradiol exhibited a similar affinity behavior to that of its natural ligand. Using BIACORE technology with an immobilized estrogen response element, we showed that 17beta-estradiol and raloxifene increased the binding of estrogen receptor alpha to the DNA, suggesting a ligand-dependent dimerization. The influence of the ligands to the binding of estrogen receptor beta was lower. We may conclude that unliganded estrogen receptor alpha binds as a monomer whereas in the presence of 10(-8) M 17beta-estradiol or higher, homodimers are formed that interact with the estrogen response element. Transactivation studies in a yeast reporter system in a ligand-dependent manner resulted in a similar potency of raloxifene to estrogen receptor beta compared to the control testosterone. Subeffective doses of raloxifene combined with 17beta-estradiol did not shift the efficiency, whereas saturating concentrations of 17beta-estradiol combined with increasing concentrations of raloxifene altered the response induced by 17beta-estradiol. In this pure system, the antagonistic activity of raloxifene could not be detected as was expected by the results from ligand competition analysis.

[1]  V. Giguère,et al.  Dominant Activity of Activation Function 1 (AF-1) and Differential Stoichiometric Requirements for AF-1 and -2 in the Estrogen Receptor α-β Heterodimeric Complex , 1999, Molecular and Cellular Biology.

[2]  Alois Jungbauer,et al.  Regulation of human estrogen receptor by phytoestrogens in yeast and human cells , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  Kathryn S. Prickett,et al.  A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification , 1988, Bio/Technology.

[4]  V. Jordan.  Estrogen receptor as a target for the prevention of breast cancer. , 1999, The Journal of laboratory and clinical medicine.

[5]  S. Cowley,et al.  A comparison of transcriptional activation by ERα and ERβ , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  C. Glass,et al.  Nuclear receptor coactivators. , 2000, Advances in pharmacology.

[7]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[8]  V. Jordan.  Targeted Antiestrogens to Prevent Breast Cancer , 1999, Trends in Endocrinology & Metabolism.

[9]  G. Kuiper,et al.  Estrogen receptor and the SERM concept , 1999, Journal of endocrinological investigation.

[10]  K. Horwitz,et al.  Nuclear receptor coactivators and corepressors. , 1996, Molecular endocrinology.

[11]  J. Gustafsson,et al.  Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. , 1998, Molecular pharmacology.

[12]  P. Chambon,et al.  The human oestrogen receptor functions in yeast , 1988, Nature.

[13]  S. Ismail.  The effects of tamoxifen on the uterus. , 1996, Current opinion in obstetrics & gynecology.

[14]  A. Jungbauer,et al.  Agonistic and synergistic activity of tamoxifen in a yeast model system. , 2000, Biochemical pharmacology.

[15]  J. Dodge,et al.  Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  C. Lyttle,et al.  Human estrogen receptor regulation in a yeast model system and studies on receptor agonists and antagonists , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  A. Cantarow,et al.  Influence of starvation on incorporation of uracil-2-C14 in liver and hepatoma RNA in the rat☆ , 1959 .

[18]  J. Gustafsson,et al.  Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. , 1997, Molecular endocrinology.

[19]  Y. Ouchi,et al.  The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. , 1998, Biochemical and biophysical research communications.

[20]  M. Dudley,et al.  Environmental estrogens induce transcriptionally active estrogen receptor dimers in yeast: activity potentiated by the coactivator RIP140. , 1999, Environmental health perspectives.

[21]  D. Ecker,et al.  Ubiquitin fusion augments the yield of cloned gene products in Escherichia coli. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. McDonnell,et al.  The Molecular Pharmacology of SERMs , 1999, Trends in Endocrinology & Metabolism.

[23]  K. Pritchard,et al.  Tamoxifen therapy in premenopausal patients with metastatic breast cancer. , 1980, Cancer treatment reports.

[24]  D. Hochner-Celnikier,et al.  Pharmacokinetics of raloxifene and its clinical application. , 1999, European journal of obstetrics, gynecology, and reproductive biology.

[25]  W. Dupont,et al.  Menopausal Estrogen Replacement Therapy and Breast Cancer , 1991, Archives of internal medicine.

[26]  S. Shiau,et al.  Activation of the human estrogen receptor by estrogenic and antiestrogenic compounds in Saccharomyces cerevisiae: a positive selection system. , 1995, Gene.

[27]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[28]  C. Klinge,et al.  Estrogen receptor interaction with co-activators and co-repressors☆ , 2000, Steroids.

[29]  K.,et al.  Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Katzenellenbogen,et al.  Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. , 1996, Molecular endocrinology.

[31]  H. Bryant,et al.  An estrogen receptor basis for raloxifene action in boneProceedings of Xth International Congress on Hormonal Steroids, Quebec, Canada, 17–21 June 1998. , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  A. Jungbauer,et al.  Monitoring of estrogen mimics by a recombinant yeast assay: synergy between natural and synthetic compounds? , 1999, The Science of the total environment.

[33]  M. Sunderland,et al.  Tamoxifen in premenopausal patients with metastatic breast cancer: a review. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  K. Grandien,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .

[35]  C. Lyttle,et al.  Estrogen Receptor Ligands Modulate Its Interaction with DNA* , 1997, The Journal of Biological Chemistry.

[36]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[37]  C. Osborne,et al.  Mechanisms for tamoxifen resistance in breast cancer: Possible role of tamoxifen metabolism , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[38]  J. Lehmann,et al.  Cloning and Characterization of Human Estrogen Receptor β Isoforms , 1998 .